Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Lung Cancer Clinical Trials

A listing of Lung Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (388) clinical trials

This trial is an open-label, single arm phase II study assessing the tolerability and anti-tumour activity of afatinib when given in combination with a fixed dose of pembrolizumab in patients with squamous NSCLC, who progressed during or after first line platinum-based standard therapy and had no prior treatment with an ...

Phase

The purpose of this research study is to see if nivolumab and ipilimumab in combination with chemotherapy is better at improving survival when compared to standard chemotherapy treatment. This study will also test the effectiveness (how well the drug works), safety, and tolerability of the nivolumab and ipilimumab combined with ...

Phase

Glesatinib is an orally administered multi-targeted tyrosine kinase inhibitor (TKI) that primarily targets the Axl and Mesenchymal-Epithelial Transition (MET) receptors. Sitravatinib is an orally-available, potent small molecule inhibitor or a closely related spectrum of receptor tyrosine kinases (RTKs) including MET, Axl, MERTK, VEGFR family, PDGFR family, KIT, FLT3, Trk family, ...

Phase

MGCD265 is an orally administered receptor tyrosine kinase inhibitor that targets MET and other receptors. This study is a Phase 2 trial of MGCD265 in patients with locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) that has activating genetic changes of the MET gene (mutation or amplification [increase ...

Phase

You are being asked to take part in this study because you have a diagnosis of advanced non-small cell lung cancer for which there are no standard therapies beyond those you may have already received. Also your tumor has been characterized as having specific changes in tumor genes which may ...

Phase

The purpose of this study is to compare any good and bad effects of using the anti-diabetic drug, metformin along with the standard of care radiation therapy and chemotherapy to using the standard of care radiation therapy and chemotherapy alone. The addition of metformin to the usual radiation and chemotherapy ...

Phase

First-line treatment for patients with non-squamous non-small cell lung cancer Patient Inclusion Criteria: Confirmed diagnosis, at least one measurable target lesion, 18+ years of age, life expectancy of >12 weeks Patient Exclusion Criteria: Small cell or carcinoid lung cancer patients are ineligible, untreated brain metastases, history of active malignancy in ...

Phase

A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1

Phase

Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer

Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) have been used to treat hypercholesterolemia. Besides the lipid lowering effects, they also act as anti-inflammatory and anti-cancer agents. Recently the investigators demonstrated a synergistic cytotoxicity between Simvastatin and Irinotecan in human lung cancer cells. Simvastatin enhances Irinotecan-induced apoptosis by inhibition of proteasome activity. ...

Phase

Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease

At the time of diagnosis, 30% of patients with small cell lung carcinoma (SCLC) will have limited stage disease, now called stage I-IIIB (IASLC). The outcome of limited disease SCLC is still poor, with a median survival of 16 to 24 months with current forms of treatment and only 15-25% ...

Phase